SI2841578T1 - Rna modulirajoči oligonukleotidi z izboljšanimi karakteristikami za zdravljenje nevromuskularnih motenj - Google Patents
Rna modulirajoči oligonukleotidi z izboljšanimi karakteristikami za zdravljenje nevromuskularnih motenjInfo
- Publication number
- SI2841578T1 SI2841578T1 SI201330728T SI201330728T SI2841578T1 SI 2841578 T1 SI2841578 T1 SI 2841578T1 SI 201330728 T SI201330728 T SI 201330728T SI 201330728 T SI201330728 T SI 201330728T SI 2841578 T1 SI2841578 T1 SI 2841578T1
- Authority
- SI
- Slovenia
- Prior art keywords
- treatment
- improved characteristics
- neuromuscular disorders
- modulating oligonucleotides
- rna modulating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261636914P | 2012-04-23 | 2012-04-23 | |
EP12165139 | 2012-04-23 | ||
PCT/NL2013/050306 WO2013162363A1 (en) | 2012-04-23 | 2013-04-23 | RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
EP13720617.3A EP2841578B1 (en) | 2012-04-23 | 2013-04-23 | RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2841578T1 true SI2841578T1 (sl) | 2017-12-29 |
Family
ID=49483552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201330728T SI2841578T1 (sl) | 2012-04-23 | 2013-04-23 | Rna modulirajoči oligonukleotidi z izboljšanimi karakteristikami za zdravljenje nevromuskularnih motenj |
Country Status (20)
Country | Link |
---|---|
US (5) | US9745576B2 (sl) |
EP (4) | EP3228712A1 (sl) |
JP (4) | JP6174678B2 (sl) |
CN (2) | CN104271741A (sl) |
AU (1) | AU2013253074C1 (sl) |
BR (1) | BR112014026285B1 (sl) |
CA (2) | CA3103101C (sl) |
DK (1) | DK2841578T3 (sl) |
ES (2) | ES2639066T3 (sl) |
HK (1) | HK1207118A1 (sl) |
HR (1) | HRP20171254T1 (sl) |
HU (1) | HUE033431T2 (sl) |
LT (1) | LT2841578T (sl) |
NZ (1) | NZ700561A (sl) |
PL (2) | PL3604536T3 (sl) |
PT (1) | PT2841578T (sl) |
RS (1) | RS56319B1 (sl) |
SI (1) | SI2841578T1 (sl) |
SM (1) | SMT201700339T1 (sl) |
WO (1) | WO2013162363A1 (sl) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2049664B1 (en) | 2006-08-11 | 2011-09-14 | Prosensa Technologies B.V. | Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders |
DK2203173T3 (en) | 2007-10-26 | 2016-02-29 | Academisch Ziekenhuis Leiden | Materials and methods for prevention of muscle diseases |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
RU2015151857A (ru) | 2008-12-02 | 2019-01-15 | Уэйв Лайф Сайенсес Джапан, Инк. | Способ синтеза модифицированных по атому фосфора нуклеиновых кислот |
WO2011005761A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc | Novel nucleic acid prodrugs and methods use thereof |
JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
EP2707486B1 (en) * | 2011-04-08 | 2020-06-10 | Zain-Luqman, Rula | Diagnosis and treatment of friedreich's ataxia |
CN107365339A (zh) | 2011-07-19 | 2017-11-21 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
CA3120918A1 (en) | 2012-01-27 | 2013-08-01 | Biomarin Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
CA3103101C (en) * | 2012-04-23 | 2023-01-17 | Biomarin Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
JP6268157B2 (ja) | 2012-07-13 | 2018-01-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
DK2906696T4 (da) | 2012-10-15 | 2023-02-27 | Ionis Pharmaceuticals Inc | Fremgangsmåder til modulering af c9orf72-ekspression |
WO2014062736A1 (en) * | 2012-10-15 | 2014-04-24 | Isis Pharmaceuticals, Inc. | Methods for monitoring c9orf72 expression |
MX370924B (es) * | 2012-10-15 | 2020-01-09 | Ionis Pharmaceuticals Inc | Composiciones para modular la expresión de c9orf72. |
EP3055414A4 (en) | 2013-10-11 | 2017-07-19 | Ionis Pharmaceuticals, Inc. | Compositions for modulating c9orf72 expression |
RU2016133035A (ru) | 2014-01-16 | 2018-02-21 | Уэйв Лайф Сайенсес Лтд. | Хиральный дизайн |
LT3119888T (lt) | 2014-03-19 | 2021-10-11 | Ionis Pharmaceuticals, Inc. | Kompozicijos, skirtos ataksino 2 raiškos moduliavimui |
US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
WO2016060919A1 (en) | 2014-10-14 | 2016-04-21 | The Board Of Regents Of The University Of Texas System | Allele selective inhibition of mutant c9orf72 foci expression by duplex rnas targeting the expanded hexanucleotide repeat |
MY181815A (en) | 2015-04-16 | 2021-01-08 | Ionis Pharmaceuticals Inc | Compositions for modulating c9orf72 expression |
US11260073B2 (en) | 2015-11-02 | 2022-03-01 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating C90RF72 |
AU2016381174A1 (en) | 2015-12-31 | 2018-05-31 | Ionis Pharmaceuticals, Inc. | Methods for reducing Ataxin-2 expression |
CA3029772A1 (en) * | 2016-07-05 | 2018-01-11 | Biomarin Technologies B.V. | Pre-mrna splice switching or modulating oligonucleotides comprising bicyclic scaffold moieties, with improved characteristics for the treatment of genetic disorders |
CN110612353A (zh) | 2017-03-03 | 2019-12-24 | 加利福尼亚大学董事会 | 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向 |
CN111819281B (zh) * | 2017-10-23 | 2024-12-31 | 普利维尔治疗公司 | 用于神经变性疾病的基因疗法 |
EA202190299A1 (ru) * | 2018-07-25 | 2021-06-11 | Ионис Фармасьютикалз, Инк. | Соединения и способы для снижения экспрессии atxn2 |
US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
US20210308273A1 (en) | 2018-08-02 | 2021-10-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
MX2022004388A (es) * | 2019-11-01 | 2022-05-06 | Alnylam Pharmaceuticals Inc | Composiciones de agentes de arni de huntingtina (htt) y metodos de uso de las mismas. |
CN115038789A (zh) | 2019-12-02 | 2022-09-09 | 塑造治疗公司 | 治疗性编辑 |
WO2022061108A2 (en) | 2020-09-17 | 2022-03-24 | Q-State Biosciences, Inc. | Therapeutic compositions for treating pain via multiple targets |
WO2022232395A2 (en) * | 2021-04-28 | 2022-11-03 | Q-State Biosciences, Inc. | Therapeutic compositions for treating pain via multiple targets |
EP4366784A1 (en) | 2021-07-09 | 2024-05-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
JP2024536132A (ja) * | 2021-09-29 | 2024-10-04 | エフ. ホフマン-ラ ロシュ アーゲー | Rna編集方法 |
WO2023164656A2 (en) * | 2022-02-25 | 2023-08-31 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating atn1 expression |
KR20250004770A (ko) | 2022-04-15 | 2025-01-08 | 다인 세라퓨틱스, 인크. | 근긴장성 이영양증을 치료하기 위한 근육 표적화 복합체 및 제제 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5695933A (en) | 1993-05-28 | 1997-12-09 | Massachusetts Institute Of Technology | Direct detection of expanded nucleotide repeats in the human genome |
AU2360195A (en) | 1994-05-05 | 1995-11-29 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
US5945290A (en) * | 1998-09-18 | 1999-08-31 | Isis Pharmaceuticals, Inc. | Antisense modulation of RhoA expression |
US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
US20050277133A1 (en) | 2001-05-18 | 2005-12-15 | Sirna Therapeutics, Inc. | RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA) |
MXPA04000162A (es) * | 2001-07-06 | 2006-05-22 | Topigen Pharma Inc | Metodos para incrementar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos. |
AU2002326589B2 (en) | 2001-08-07 | 2008-06-05 | University Of Delaware | Compositions and methods for the prevention and treatment of Huntington's disease |
US20060074034A1 (en) | 2001-09-17 | 2006-04-06 | Collins Douglas A | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
US20050255086A1 (en) | 2002-08-05 | 2005-11-17 | Davidson Beverly L | Nucleic acid silencing of Huntington's Disease gene |
US7892793B2 (en) | 2002-11-04 | 2011-02-22 | University Of Massachusetts | Allele-specific RNA interference |
US7655785B1 (en) | 2002-11-14 | 2010-02-02 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof |
US7514551B2 (en) | 2003-04-03 | 2009-04-07 | Enzo Life Sciences, Inc. | Multisignal labeling reagents, and processes and uses therefor |
CA2526893C (en) | 2003-05-14 | 2010-10-26 | Japan Science And Technology Agency | Inhibition of the expression of huntingtin gene |
EP1844148A2 (en) | 2005-01-31 | 2007-10-17 | University of Iowa Research Foundation | Nucleic acid silencing of huntington's disease gene |
US20070299027A1 (en) | 2006-01-26 | 2007-12-27 | Gene Hung | Compositions and their uses directed to huntingtin |
CN101501193B (zh) * | 2006-08-11 | 2013-07-03 | 普罗森那技术公司 | 用于治疗与dna重复不稳定性相关的遗传病的方法和手段 |
EP2049664B1 (en) * | 2006-08-11 | 2011-09-14 | Prosensa Technologies B.V. | Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders |
EP2505211B1 (en) | 2007-07-12 | 2020-04-08 | BioMarin Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
JP2011510678A (ja) * | 2008-02-08 | 2011-04-07 | プロセンサ ホールディング ビーブイ | Dna反復不安定性関連遺伝性障害を治療するための方法及び手段 |
US8703730B2 (en) | 2008-07-10 | 2014-04-22 | Regenesance B.V. | Complement antagonists and uses thereof |
US20110218334A1 (en) | 2008-07-11 | 2011-09-08 | Alnylam Pharmaceuticals, Inc. | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS |
AU2009276763B2 (en) | 2008-07-29 | 2015-07-16 | The Board Of Regents Of The University Of Texas Sytem | Selective inhibition of polyglutamine protein expression |
KR101840618B1 (ko) * | 2008-12-04 | 2018-03-20 | 큐알엔에이, 인크. | 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료 |
SG176716A1 (en) | 2009-06-08 | 2012-01-30 | Miragen Therapeutics | CHEMICAL MODIFICATION MOTIFS FOR miRNA INHIBITORS AND MIMETICS |
WO2011097641A1 (en) | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Methods and compositions useful in treatment of diseases or conditions related to repeat expansion |
WO2011097614A1 (en) * | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Mehods and compositions useful in diseases or conditions related to repeat expansion |
NZ603606A (en) | 2010-05-28 | 2015-06-26 | Sarepta Therapeutics Inc | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
AU2011282243B2 (en) | 2010-07-19 | 2016-09-22 | Ionis Pharmaceuticals, Inc. | Modulation of nuclear-retained RNA |
US8513211B2 (en) | 2010-08-20 | 2013-08-20 | Replicor Inc. | Oligonucleotide chelate complexes |
EP2673361B1 (en) | 2011-02-08 | 2016-04-13 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
WO2012150960A1 (en) | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Peptide oligonucleotide conjugates |
ES2832531T3 (es) | 2011-11-30 | 2021-06-10 | Sarepta Therapeutics Inc | Oligonucleótidos para el tratamiento de enfermedades por expansión de repeticiones |
EP2812342B1 (en) | 2012-02-08 | 2017-11-15 | Ionis Pharmaceuticals, Inc. | Modulation of rna by repeat targeting |
CA3103101C (en) * | 2012-04-23 | 2023-01-17 | Biomarin Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders |
-
2013
- 2013-04-23 CA CA3103101A patent/CA3103101C/en active Active
- 2013-04-23 RS RS20170765A patent/RS56319B1/sr unknown
- 2013-04-23 NZ NZ700561A patent/NZ700561A/en unknown
- 2013-04-23 ES ES13720617.3T patent/ES2639066T3/es active Active
- 2013-04-23 ES ES19194127T patent/ES2983421T3/es active Active
- 2013-04-23 BR BR112014026285-3A patent/BR112014026285B1/pt active IP Right Grant
- 2013-04-23 CN CN201380021505.XA patent/CN104271741A/zh active Pending
- 2013-04-23 PL PL19194127.7T patent/PL3604536T3/pl unknown
- 2013-04-23 SI SI201330728T patent/SI2841578T1/sl unknown
- 2013-04-23 PT PT137206173T patent/PT2841578T/pt unknown
- 2013-04-23 JP JP2015506930A patent/JP6174678B2/ja active Active
- 2013-04-23 LT LTEP13720617.3T patent/LT2841578T/lt unknown
- 2013-04-23 DK DK13720617.3T patent/DK2841578T3/en active
- 2013-04-23 HU HUE13720617A patent/HUE033431T2/en unknown
- 2013-04-23 SM SM20170339T patent/SMT201700339T1/it unknown
- 2013-04-23 CN CN201811488693.8A patent/CN110025628B/zh active Active
- 2013-04-23 PL PL13720617T patent/PL2841578T3/pl unknown
- 2013-04-23 AU AU2013253074A patent/AU2013253074C1/en active Active
- 2013-04-23 EP EP17170330.9A patent/EP3228712A1/en not_active Ceased
- 2013-04-23 WO PCT/NL2013/050306 patent/WO2013162363A1/en active Application Filing
- 2013-04-23 EP EP19194127.7A patent/EP3604536B1/en active Active
- 2013-04-23 CA CA2870697A patent/CA2870697C/en active Active
- 2013-04-23 EP EP13720617.3A patent/EP2841578B1/en active Active
- 2013-04-23 EP EP24173123.1A patent/EP4400169A3/en active Pending
-
2014
- 2014-10-23 US US14/522,002 patent/US9745576B2/en active Active
-
2015
- 2015-08-11 HK HK15107745.6A patent/HK1207118A1/xx unknown
-
2017
- 2017-07-06 JP JP2017133005A patent/JP2018027080A/ja active Pending
- 2017-08-14 US US15/676,569 patent/US20180066256A1/en not_active Abandoned
- 2017-08-16 HR HRP20171254TT patent/HRP20171254T1/hr unknown
-
2019
- 2019-10-22 US US16/660,416 patent/US11345915B2/en active Active
-
2020
- 2020-07-03 JP JP2020115868A patent/JP7459691B2/ja active Active
-
2022
- 2022-04-25 US US17/728,336 patent/US20220389421A1/en active Pending
- 2022-06-08 JP JP2022093254A patent/JP2022126711A/ja active Pending
-
2024
- 2024-06-24 US US18/752,689 patent/US20250011784A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20171254T1 (hr) | Oligonukleotidi koji moduliraju rnk s poboljšanim karakteristikama za liječenje neuromišićnih poremećaja | |
IL266159A (en) | Treatment of circadian rhythm disorders | |
HK1209456A1 (en) | Oligonucleotide for the treatment of muscular dystrophy patients | |
IL263661A (en) | Combination therapy for the treatment of glioblastoma | |
EP2827856A4 (en) | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MUSCLE DISEASES | |
IL233715A0 (en) | Treatment of diseases related to the circadian rhythm | |
LT2838539T (lt) | Estrogeniniai dariniai, skirti naudoti neurologinių sutrikimų gydymui | |
HK1215173A1 (zh) | 治療金黃色葡萄球菌相關疾病的方法 | |
HK1201878A1 (en) | Oligonucleotides for modulating gene expression and uses thereof | |
HK1203054A1 (en) | Dinuceloside polyphosphates for the treatment of pain | |
ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
HK1214293A1 (zh) | 反義寡核苷酸和利用其治療細胞增殖性疾病的方法 | |
HK1243733A1 (zh) | 用於治療神經肌肉障礙的具有改善特性的rna調節寡核苷酸 | |
AU2012900796A0 (en) | Pain treatment |